Table 1.

Baseline Characteristics of Participants by Timing of Antiretroviral Therapy Initiation per CD4-Stratified Strategy, Integrating Tuberculosis and Antiretroviral Treatment Study, 2007–2009

Baseline Characteristic	All Patients (n = 395)		Timing of Antiretroviral Therapy Initiation				P Value
			Per Strategy (n = 183)		Not Per Strategy (n = 212)
	No.	%	No.	%	No.	%
Sex
Female	231	58.5	103	56.3	128	60.4	0.41
Male	164	41.5	80	43.7	84	39.6
Age, yearsa	38 (32–45)		38 (32–45)		38 (32–45)		0.97
Age, years
<30	65	16.5	32	17.5	33	15.6	0.61
30–39	158	40.0	73	39.9	85	40.1	0.97
40–49	129	32.7	56	30.6	73	34.4	0.42
≥50	43	10.9	22	12.0	21	9.9	0.50
Tuberculosis type
Smear positive, pulmonary	139	35.2	71	38.8	68	32.1	0.16
Smear negative, pulmonary	176	44.6	77	42.1	99	46.7	0.36
Extrapulmonary	80	20.3	35	19.1	45	21.2	0.60
CD4 count, cells/mm3a	131 (63–224)		151 (77–243)		113 (60–190)		0.002
CD4 count, cells/mm3
<50	77	19.5	33	18.0	44	20.8	0.50
50–99	64	16.2	21	11.5	43	20.3	0.02
100–199	136	34.4	61	33.3	75	35.4	0.67
200–350	118	29.9	68	37.2	50	23.6	0.003
Body mass indexa,b	17.8 (16.5–19.7)		17.7 (16.4–19.6)		17.8 (16.6–19.8)		0.35
Body mass indexb
Underweight (<18.5)	234	59.2	114	62.3	120	56.6	0.25
Normal (18.5–24.9)	148	37.5	64	35.0	84	39.6	0.34
Overweight (25.0–29.9)	11	2.8	4	2.2	7	3.3	0.56
Obese (≥30.0)	2	0.5	1	0.6	1	0.5	1.0
Toleration of tuberculosis drugs	322	81.5	175	95.6	147	69.3	<0.001
Contraindication to any ARV drug	24	6.1	7	3.8	17	8.0	0.09
WHO clinical stage 4	90	22.8	41	22.4	49	23.1	0.87

Abbreviations: ARV, antiretroviral; WHO, World Health Organization.

^a Median (interquartile range).

^b Weight (kg)/height (m)².